<p>Immix Biopharma, Inc.（纳斯达克股票代码：IMMX - 获取免费报告）在六月份成为空头头寸显著增加的目标。截至 6 月 15 日，空头头寸总计 473,100 股，比 5 月 31 日的 338,700 股增加了 39.7%。根据平均每日交易量 131,400 股，目前的空头头寸比率为 3.6 天。目前，公司股份中有 3.1% 被做空。</p>
<p>获取 <strong>Immix Biopharma</strong> 警报：</p>
<h2>华尔街分析师观点</h2>
<p>另外，HC Wainwright 在周一的一份报告中开始对 Immix Biopharma 进行覆盖。他们对该股发出了 “买入” 评级，并设定了 7.00 美元的股价目标。</p>
<p><strong>查看我们对 Immix Biopharma 的最新分析</strong></p>
<h2>Immix Biopharma 交易上涨 7.1%</h2>
<p>IMMX 周一在交易时间内上涨了 0.14 美元，达到 2.12 美元。公司股票交易量为 109,687 股，相比其平均交易量 209,798 股有所下降。Immix Biopharma 的 12 个月最低价为 1.55 美元，最高价为 7.75 美元。该公司的市值为 5599 万美元，市盈率为-2.28，贝塔系数为 0.17。公司的 50 天移动平均价为 2.16 美元，200 天移动平均价为 3.42 美元。</p>
<p>Immix Biopharma（纳斯达克股票代码：IMMX - 获取免费报告）上次公布季度财报是在 5 月 9 日星期四。公司报告该季度每股收益为（0.22）美元，超过了（0.23）美元的共识预期。研究分析师群体预计，Immix Biopharma 今年财政年度的每股收益将为-0.93 美元。</p>
<h2>机构投资者对 Immix Biopharma 的看法</h2>
<p>一些对冲基金最近买卖了该股的股份。Tocqueville Asset Management L.P.在第一季度将其在 Immix Biopharma 的持股增加了 89.0%。Tocqueville Asset Management L.P.现在拥有该公司的 37,800 股股份，价值 116,000 美元，比上一季度增加了 17,800 股。Tritonpoint Wealth LLC 在第一季度收购了 Immix Biopharma 的新股份，价值 75,000 美元。Jump Financial LLC 在第四季度购买了 Immix Biopharma 的新股份，价值 128,000 美元。Private Advisor Group LLC 在第四季度收购了 Immix Biopharma 的新股份，价值 690,000 美元。最后，OLD National Bancorp IN 在第四季度购买了 Immix Biopharma 的新股份，价值 69,000 美元。机构投资者和对冲基金拥有公司股份的 11.26%。</p>
<h2>Immix Biopharma 公司简介（获取免费报告）</h2>
<p>Immix Biopharma, Inc 是一家临床阶段的生物制药公司，致力于在美国和澳大利亚开发肿瘤学和炎症领域的组织特异性治疗药物。该公司正在开发 IMX-110，该药正在进行软组织肉瘤和实体肿瘤的 1b/2a 期临床试验；IMX-111，一种用于治疗结直肠癌的组织特异性生物制剂；以及 IMX-120，一种用于治疗溃疡性结肠炎和严重克罗恩病的组织特异性生物制剂。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票比 Immix Biopharma 更好</li>
<li>卖空：如何做空股票</li>
<li>这三家顶级银行通过通过联邦压力测试后提高股息</li>
<li>为什么特别股息对收入投资者来说是一个令人愉快的惊喜</li>
<li>搭乘 Lyft 股票在下半年实现两位数增长</li>
<li>什么是纳斯达克证券交易所？</li>
<li>艾礼莉利股价上涨：GLP-1 Zepbound 瞄准睡眠呼吸暂停市场</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 伊隆的下一个 IPO 可能比特斯拉还要大（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTgx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTgx"/></p>
<h2>您现在是否应该投资 1000 美元购买 Immix Biopharma？</h2>
<p>在考虑投资 Immix Biopharma 之前，您可能希望听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票...而 Immix Biopharma 不在名单上。</p>
<p>尽管 Immix Biopharma 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

IMMX

<p>Immix Biopharma（纳斯达克股票代码：IMMX）在六月份经历了空头头寸的显著增加，较上个月增长了 39.7%。该公司的股票目前被空头卖出比率为 3.1%，覆盖天数比率为 3.6 天。股价为$2.12，12 个月最高价为$7.75，最低价为$1.55。Immix Biopharma 是一家专注于肿瘤学和炎症领域的组织特异性治疗药物开发的临床阶段生物制药公司</p>

<p>Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 473,100 shares, an increase of 39.7% from the May 31st total of 338,700 shares. Based on an average daily trading volume, of 131,400 shares, the short-interest ratio is currently 3.6 days. Currently, 3.1% of the company's shares are short sold.</p>
<div class="lb-trans"><p>Immix Biopharma, Inc.（纳斯达克股票代码：IMMX - 获取免费报告）在六月份成为空头头寸显著增加的目标。截至 6 月 15 日，空头头寸总计 473,100 股，比 5 月 31 日的 338,700 股增加了 39.7%。根据平均每日交易量 131,400 股，目前的空头头寸比率为 3.6 天。目前，公司股份中有 3.1% 被做空。</p>
</div><p>Get <strong>Immix Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Immix Biopharma</strong> 警报：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, HC Wainwright initiated coverage on Immix Biopharma in a report on Monday. They issued a &#34;buy&#34; rating and a $7.00 price objective on the stock.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在周一的一份报告中开始对 Immix Biopharma 进行覆盖。他们对该股发出了 “买入” 评级，并设定了 7.00 美元的股价目标。</p>
</div><p><strong>View Our Latest Analysis on Immix Biopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Immix Biopharma 的最新分析</strong></p>
</div><h2>Immix Biopharma Trading Up 7.1 %</h2>
<div class="lb-trans"><h2>Immix Biopharma 交易上涨 7.1%</h2>
</div><p>IMMX traded up $0.14 during trading hours on Monday, hitting $2.12. 109,687 shares of the company's stock were exchanged, compared to its average volume of 209,798. Immix Biopharma has a 12-month low of $1.55 and a 12-month high of $7.75. The firm has a market cap of $55.99 million, a P/E ratio of -2.28 and a beta of 0.17. The firm has a 50 day moving average of $2.16 and a 200 day moving average of $3.42.</p>
<div class="lb-trans"><p>IMMX 周一在交易时间内上涨了 0.14 美元，达到 2.12 美元。公司股票交易量为 109,687 股，相比其平均交易量 209,798 股有所下降。Immix Biopharma 的 12 个月最低价为 1.55 美元，最高价为 7.75 美元。该公司的市值为 5599 万美元，市盈率为-2.28，贝塔系数为 0.17。公司的 50 天移动平均价为 2.16 美元，200 天移动平均价为 3.42 美元。</p>
</div><p>Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, research analysts expect that Immix Biopharma will post -0.93 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Immix Biopharma（纳斯达克股票代码：IMMX - 获取免费报告）上次公布季度财报是在 5 月 9 日星期四。公司报告该季度每股收益为（0.22）美元，超过了（0.23）美元的共识预期。研究分析师群体预计，Immix Biopharma 今年财政年度的每股收益将为-0.93 美元。</p>
</div><h2>Institutional Investors Weigh In On Immix Biopharma</h2>
<div class="lb-trans"><h2>机构投资者对 Immix Biopharma 的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the stock. Tocqueville Asset Management L.P. raised its holdings in Immix Biopharma by 89.0% in the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company's stock valued at $116,000 after acquiring an additional 17,800 shares in the last quarter. Tritonpoint Wealth LLC acquired a new stake in shares of Immix Biopharma in the 1st quarter valued at $75,000. Jump Financial LLC purchased a new stake in shares of Immix Biopharma during the 4th quarter worth $128,000. Private Advisor Group LLC acquired a new position in shares of Immix Biopharma during the fourth quarter worth $690,000. Finally, OLD National Bancorp IN purchased a new position in Immix Biopharma in the fourth quarter valued at $69,000. Institutional investors and hedge funds own 11.26% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近买卖了该股的股份。Tocqueville Asset Management L.P.在第一季度将其在 Immix Biopharma 的持股增加了 89.0%。Tocqueville Asset Management L.P.现在拥有该公司的 37,800 股股份，价值 116,000 美元，比上一季度增加了 17,800 股。Tritonpoint Wealth LLC 在第一季度收购了 Immix Biopharma 的新股份，价值 75,000 美元。Jump Financial LLC 在第四季度购买了 Immix Biopharma 的新股份，价值 128,000 美元。Private Advisor Group LLC 在第四季度收购了 Immix Biopharma 的新股份，价值 690,000 美元。最后，OLD National Bancorp IN 在第四季度购买了 Immix Biopharma 的新股份，价值 69,000 美元。机构投资者和对冲基金拥有公司股份的 11.26%。</p>
</div><h2>Immix Biopharma Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Immix Biopharma 公司简介（获取免费报告）</h2>
</div><p>Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.</p>
<div class="lb-trans"><p>Immix Biopharma, Inc 是一家临床阶段的生物制药公司，致力于在美国和澳大利亚开发肿瘤学和炎症领域的组织特异性治疗药物。该公司正在开发 IMX-110，该药正在进行软组织肉瘤和实体肿瘤的 1b/2a 期临床试验；IMX-111，一种用于治疗结直肠癌的组织特异性生物制剂；以及 IMX-120，一种用于治疗溃疡性结肠炎和严重克罗恩病的组织特异性生物制剂。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Immix Biopharma</li>
<li>Short Selling: How to Short a Stock</li>
<li>These Top 3 Banks Raise Dividends After Passing Fed Stress Test</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票比 Immix Biopharma 更好</li>
<li>卖空：如何做空股票</li>
<li>这三家顶级银行通过通过联邦压力测试后提高股息</li>
<li>为什么特别股息对收入投资者来说是一个令人愉快的惊喜</li>
<li>搭乘 Lyft 股票在下半年实现两位数增长</li>
<li>什么是纳斯达克证券交易所？</li>
<li>艾礼莉利股价上涨：GLP-1 Zepbound 瞄准睡眠呼吸暂停市场</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Elon’s Next IPO Could be Bigger than Tesla (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 伊隆的下一个 IPO 可能比特斯拉还要大（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTgx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8581&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Immix Biopharma right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买 Immix Biopharma？</h2>
</div><p>Before you consider Immix Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Immix Biopharma 之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票...而 Immix Biopharma 不在名单上。</p>
</div><p>While Immix Biopharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Immix Biopharma 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Immix Biopharma, Inc. (NASDAQ:IMMX) 空头头寸显著增加